Table 3. Preoperative chemoradiotherapy versus surgery alone.
| Author | Treatment | Histology | n | Resection rate (%) | Mortality (%) | MST (months) | Survival rate (%) | OS |
|---|---|---|---|---|---|---|---|---|
| Nygaard (1992) | CDDP/BLM/35 Gy + Surgery | SCC | 53 | 55 (R0) | 24 | NA | 23 (2 year) | NS |
| Surgery alone | 50 | 37 (R0) | 13 | NA | 13 (2 year) | |||
| Apinop (1994) | 5-FU/CDDP/40 Gy + Surgery | SCC | 35 | NA | 14 | 10 | 26 (3 year) | NS |
| Surgery alone | 34 | NA | 15 | 7 | 20 (3 year) | |||
| Le Prise (1994) | 5-FU/CDDP/20 Gy + Surgery | SCC | 41 | 85 (R0) | 9 | 11 | 19 (3 year) | NS |
| Surgery alone | 45 | 84 (R0) | 7 | 11 | 14 (3 year) | |||
| Bosset (1997) | CDDP/37 Gy + Surgery | SCC | 143 | 81 (R0) | 12 | 19 | 39 (3 year) | NS |
| Surgery alone | 139 | 69 (R0) | 4 | 19 | 37 (3 year) | |||
| Urba (2001) | 5-FU/CDDP/VBL/45 Gy + Surgery | AC/SCC | 50 | 90 (R0) | 2 | 17 | 30 (3 year) | NS |
| Surgery alone | 50 | 90 (R0) | 4 | 18 | 16 (3 year) | |||
| Lee (2004) | 5-FU/CDDP/46 Gy + Surgery | SCC | 51 | 69 (R0) | 2 | 28 | 55 (2 year) | NS |
| Surgery alone | 50 | 84 (R0) | 2 | 27 | 57 (2 year) | |||
| Burmeister (2005) | 5-FU/CDDP/35 Gy + Surgery | AC/SCC | 128 | 80 (R0) | 5 | 22 | NA | NS |
| Surgery alone | 128 | 59 (R0) | 5 | 19 | NA | |||
| Natsugoe (2006) | 5-FU/CDDP/40 Gy + Surgery | SCC | 22 | NA | 5 | NA | 57 (5year) | NS |
| Surgery alone | 23 | NA | 0 | NA | 41 (5 year) | |||
| Tepper (2008) | 5-FU/CDDP/50.4 Gy + Surgery | AC/SCC | 30 | 86 | 0 | 54 | 39 (5 year) | p = 0.002 |
| Surgery alone | 26 | 88 | 4 | 22 | 16 (5 year) | |||
| Lv (2010) | PTX/CDDP/41.4 Gy + Surgery | SCC | 80 | 97 (R0) | 3.8 | 53 | 44 (5 year) | p = 0.005 |
| Surgery alone | 80 | 80 (R0) | 0 | 36 | 34 (5 year) | |||
| Van Hagen (2012) | 5-FU/CDDP/45 Gy + Surgery | AC/SCC | 98 | 94 (R0) | 11.1 | 32 | 41 (5 year) | NS |
| Surgery alone | 97 | 92 (R0) | 3.4 | 41 | 34 (5 year) | |||
| Mariette (2014) | PTX/CBDCA/41.4 Gy + Surgery | AC/SCC | 175 | 92 (R0) | 3.4 | 49 | 59 (3 year) | p = 0.003 |
| Surgery alone | 188 | 69 (R0) | 3.8 | 24 | 44 (3 year) | |||
MST: mean survival time; OS: overall survival; CDDP: cisplatin; BLM: bleomysin; SCC: squamous cell carcinoma; NS: not significant; 5-FU: 5 fluorouracil; NA: not available; VL: vinblastine; AC: adenocarcinoma; PTX: paclitaxel; CBDCA: carboplatin